Based on the pharmacodynamics of PIP as an anti-inflammatory that disrupts the NLRP3 inflammasome cascade, in vivo experiments were done to demonstrate the preventive (protocol I) and curative (protocol II) action of PIP on anti-arthritis gout resulting from MSU deposition. This evidence concerns the gene NLRP3 and gout.